IN CONJUNCTION WITH OUR MEETING YOU ARE INVITED TO ATTEND A PRESENTATION ON LYNPARZA® (OLAPARIB)
Treatment of mCRPC with LYNPARZA: An oral therapy for patients with HRR gene mutations following progression on enzalutamide or abiraterone
INDICATION: LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
May 6, 2021
06:30 PM – 07:30 PM
Eastern Daylight Time
PRESENTED BY
Marc Matrana, MD, FACP, MS
Director, Precision Therapies, Associate Director of Clinical Cancer Research
Ochsner Cancer Institute
LOCATION
Christian's
1693 Bass Road
Macon, GA 31210
RSVP IS REQUIRED BY
5/3/2021
To register or for more information, contact
Melanie Price at +1 (478) 719-8965/Melanie.price@astrazeneca.com
LYNPARZA IS AN ORAL THERAPY APPROVED FOR PATIENTS WITH HRR GENE-MUTATED mCRPC FOLLOWING PROGRESSION AFTER ENZALUTAMIDE OR ABIRATERONE